Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | TDO2 | P48775 | 1/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14607854 | 0.78 | IDO1 (0.53) | IDO1TDO2AOC3SLC7A5 | |
| SCHEMBL14528136 | 0.78 | IDO1 (0.45) | IDO1TDO2AOC3HDAC4HDAC7 | |
| SCHEMBL2336423 | 0.75 | IDO1 (0.52) | IDO1TDO2 | |
| SCHEMBL1505811 | 0.74 | SCN1A (0.50) | — | |
| SCHEMBL14607856 | 0.74 | IDO1 (0.45) | IDO1TDO2AOC3 | |
| SCHEMBL14528133 | 0.74 | IDO1 (0.61) | IDO1TDO2 | |
| SCHEMBL14607959 | 0.74 | IDO1 (0.57) | IDO1TDO2 | |
| SCHEMBL792133 | 0.74 | IDO1 (0.56) | IDO1TDO2AOC3HDAC4HDAC7 | |
| SCHEMBL5540257 | 0.73 | IDO1 (0.51) | IDO1TDO2AOC3HDAC4HDAC7 | |
| SCHEMBL10335030 | 0.72 | HDAC4 (0.46) | IDO1TDO2AOC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003632-B2 | administerine tacrine, a tacrine analog, fasciculin, metrifonate, heptyl-physostigmine, norpyridostigmine, norneostigmine, huperzine A or an analogue, physostigmine, heptyl-physostigmine etc. free of galantamine to reduce the level of a proinflammatory cytokine | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-08-23 | — | — | US | disclosed |
| US-20080070901-A1 | Cholineterase inhibitors for treating inflammation | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH | 2008-03-20 | — | — | US | disclosed |
| US-20050222123-A1 | Cholinesterase inhibitors for treating inflammation | NORTH SHORE-LONG ISLAND JEWISH RESEARCH INSTITUTE (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005072713-A2 | CHOLINESTERASE INHIBITORS FOR TREATING INFLAMMATION | THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH (US) | 2005-08-11 | — | — | WO | disclosed |
| US-6248750-B1 | CHOLINERGIC FUNCTION AGONISTS FOR MEMORY ENHANCEMENT | HOECHST ROUSSEL PHARMACEUTICALS | 2001-06-19 | — | — | US | disclosed |
| US-6075144-A | ABILITY TO INHIBIT ACETYLCHOLINESTERASE; TREATS ALZHEIMER,S DISEASE | HOECHST MARION ROUSSEL, INC. (US) | 2000-06-13 | — | — | US | disclosed |
| US-5401749-A | Memory enhancers, cholinergic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-03-28 | — | — | US | disclosed |
| US-5391553-A | Increasing cholinergic functionin mammals | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1995-02-21 | — | — | US | disclosed |
| US-5389629-A | Increase cholinergic function | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1995-02-14 | — | — | US | disclosed |
| EP-0278499-B1 | 9-Amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST ROUSSEL PHARMA (US) | 1994-09-28 | — | — | EP | disclosed |
| US-4806646-A | Substituted 9-amino-spiro[cycloalkyl[B]quinoline-2,1'cycloalkanes] | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0288852-A1 | 9-Hydroxyamino tetrahydro-acridines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0287977-A2 | Fused heteroalkylene quinolinamines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-26 | — | — | EP | disclosed |
| EP-0285018-A2 | Substituted 9-Amino-Spiro [cycloalkyl[b]quinoline-2,1'cycloalkanes], a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-10-05 | — | — | EP | disclosed |
| EP-0282959-A2 | Substituted 9-amino-tetrahydro-acridines and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-09-21 | — | — | EP | disclosed |
| EP-0278499-A2 | 9-Amino-1,4-ethano-1,2,3,4-tetrahydroacridine and related compounds, intermediates and a process for the preparation thereof and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1988-08-17 | — | — | EP | disclosed |
| US-4762841-A | Substituted 9-amino-spiro(cycloalkyl(b)quinoline-2,1'cycloalkanes) | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1988-08-09 | — | — | US | disclosed |
| US-4754050-A | COGNITION ACTIVATORS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1988-06-28 | — | — | US | disclosed |
| US-4695573-A | COGNITION ACTIVATORS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0179383-A2 | 9-Amino-1,2,3,4-tetrahydroacridin-1-ol and related compounds, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070901-A1 | Cholineterase inhibitors for treating inflammation | ACHE, BCHE, CHAT | IDO1 157/4885TDO2 1236/4885AOC3 920/4885 |
| US-20050222123-A1 | Cholinesterase inhibitors for treating inflammation | ACHE, BCHE, CHAT | IDO1 83/4885TDO2 1003/4885AOC3 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.